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Abstract
Background: Platelet derived growth factor receptor (PDGFR) activity is deregulated in human GBM due to amplification
and rearrangement of the PDGFR-alpha gene locus or overexpression of the PDGF ligand, resulting in the activation of
downstream kinases such as phosphatidylinositol 3-kinase (PI3K), Akt, and mammalian target of rapamycin (mTOR).
Aberrant PDGFR signaling is observed in approximately 25-30% of human GBMs, which are frequently molecularly classified
as the proneural subclass. It would be valuable to understand how PDGFR driven GBMs respond to Akt and mTOR
inhibition.
Methodology/Principal Findings: Using genetically engineered PTEN-intact and PTEN-deficient PDGF-driven mouse models
of GBM that closely mimic the histology and genetics of the human PDGF subgroup, we investigated the effect of inhibiting
Akt and mTOR alone or in combination in vitro and in vivo. We used perifosine and CCI-779 to inhibit Akt and mTOR,
respectively. Here, we show in vitro data demonstrating that the most effective inhibition of Akt and mTOR activity in both
PTEN-intact and PTEN-null primary glioma cell cultures is obtained when using both inhibitors in combination. We next
investigated if the effects we observed in culture could be duplicated in vivo by treating mice with gliomas for 5 days. The in
vivo treatments with the combination of CCI-779 and perifosine resulted in decreased Akt and mTOR signaling, which
correlated to decreased proliferation and increased cell death independent of PTEN status, as monitored by immunoblot
analysis, histology and MRI.
Conclusions/Significance: These findings underline the importance of simultaneously targeting Akt and mTOR to achieve
significant down-regulation of the PI3K pathway and support the rationale for testing the perifosine and CCI-779
combination in the human PDGF-subgroup of GBM.
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Introduction
Glioblastoma multiforme (GBM) is both the most common and
the most malignant primary brain tumor in adults. Despite
aggressive therapy, which includes surgical resection, radiation,
and chemotherapy, the survival of GBM patients is poor with
median survival of around 1 year [1]. The only recent significant
increase in survival for these patients has been obtained by using a
combination of radiation therapy with concomitant and adjuvant
alkylating chemotherapy (temozolomide), extending mean overall
survival by 2.5 months [2]. Many new forms of treatment have
been tested, including immunotherapy and gene therapy, but
outcomes have not yet been impressive and the development of
new treatment modalities is urgent. The PI3K/Akt signaling
pathway can be upregulated in gliomas through several mecha-
nisms, most commonly through mutation or loss of heterozygosity
of PTEN or through amplification/over-expression of critical
growth factor receptors such as EGFR and PDGFR. Activation of
PLoS ONE | www.plosone.org 1 January 2011 | Volume 6 | Issue 1 | e14545the PI3K pathway is significantly associated with increased tumor
grade, decreased levels of apoptosis, and adverse clinical outcome
in human gliomas [3]. Activated PI3K generates phosphatidyli-
nositol 3,4,5-triphosphate (PIP3), which is required for Akt
activation [4]. Akt then signals to several downstream targets,
including the mammalian target of rapamycin (mTOR). This
subsequently leads to increased phosphorylation of eIF4E binding
protein 1 (4EBP1) and activation of p70 ribosomal S6 protein
kinase (p70
S6K), which phosphorylates S6 ribosomal protein [5].
Perifosine is alkylphospholipid that interferes with recruitment
of Akt to plasma membrane and inhibits Akt phosphorylation
and activation. Several mouse and cell culture experiments have
demonstrated that perifosine has antitumor activity, which is
especially pronounced when combined with radiation [6] or
temozolomide [7]. Unfortunately, phase II clinical trials of
perifosine as a single agent on recurrent prostate cancer,
adenocarcinomas, and melanomas have been disappointing
[8,9,10].
CCI-779 is a lipid soluble analog of rapamycin that inhibits
mTOR by binding to FKBP-12, resulting in cell cycle arrest and
decreased growth of several human cancer cell lines [11,12]. Data
from our laboratory using CCI-779 in a mouse model of PDGF-B
driven low-grade gliomas demonstrated dramatic anti-proliferative
effect in these tumors [13]. In addition to decreased proliferation,
there are also many reports of rapamycin promoting pro-apoptotic
signals [14,15], but there is also data supporting its promoting cell
survival [16]. Again, data from our lab demonstrated that the
blockade of mTOR with CCI-779 resulted in regional apoptosis
and conversion in the character of surviving tumor cells from
astrocytoma to oligodendroglioma in a mouse model of Akt+K-
Ras-induced GBMs [17].
Data from cell lines and from xenograft experiments indicate
the existence of a strong correlation between the anti-proliferative
effects of rapamycin analogues and the loss of phosphatase and tensin
homologue gene (PTEN) [18]. These data lead to the idea that
rapamycin and analogs (CCI-779 and RAD001) may be effective
in tumors with an activated PI3K-Akt pathway. However, despite
pre-clinical data indicating that rapamycin and its analogs have
anti-tumor activity, early clinical trials did not show universal anti-
tumor activity, especially for tumors with high levels of PI3K-Akt
activity, such as glioblastoma [11,19] and breast cancers [20]. A
phase I trial of rapamycin for patients with recurrent PTEN-
deficient GBMs demonstrated that rapamycin treatment in
around 50% of patients led to Akt activation, which was suggested
to be due to the negative feedback [21,22]. This activation of Akt
was associated with shorter time-to-progression during post-
surgical maintenance rapamycin therapy [21].
Quantification of growth rates and response to therapy of
orthotopic glioma models has been established using MRI
[23,24,25]. Conventional MRI provides an opportunity to non-
invasively follow gross tumor morphology and its evolution over
time by exploiting a variety of endogenous tissue properties that
allows assessment of gross tumor extent on the resultant MRI
contrasts such as T2-weighted and gadolinium-enhanced T1-
weighted images. Diffusion-weighted MRI (DW-MRI) can also be
used to obtain information related to the microscopic cellular
environment of solid tumors [25,26,27]. Since water diffusion
values are strongly affected by cellular density which impedes
water mobility, DW-MRI can be used to characterize highly
cellular regions of tumors versus acellular regions, to distinguish
cystic regions from solid regions, as well as to detect treatment
response which is manifested as a change in cellularity within the
tumor over time [28]. In this context, we applied DW-MRI to
evaluate the effects of molecularly targeted agents using changes in
water diffusion values as a surrogate for the underlying changes in
tissue structure at the cellular level. MRI provided an opportunity
to quantitatively and serially follow therapeutic-induced changes
in brain tumor volumes and cellularity.
Based on the results of a phase I human GBM trial [21], we
designed a traditional pre-clinical trial using mouse models. Our
pre-clinical trial aimed to use the observations made from the
human clinical trial [21] and cell line experiments [29], which
suggested the possible benefits of using a combination of Akt
inhibitors with mTOR inhibitors. Previous studies using various
cell lines, including glioma cell lines, have shown enhanced
sensitivity of PTEN-deficient tumors to mTOR inhibition [30],
which later was demonstrated to be due to Akt dependent
regulation of Cyclin D1 and c-myc expression [31]. It has been also
hypothesized that PTEN status may determine the effectiveness of
blocking both the PI3K and mTOR pathways [32]. Other studies
utilized PDGF-B driven cortical gliomas to show that perifosine
cooperates with temozolomide to arrest cell proliferation in vivo [7].
Later, another study using PDGF-B driven Ink4A-ARF null brain
stem glioma model demonstrated non-effectiveness of perifosine in
a pre-clinical trial as a single agent [33]. In our study we used
PDGF-B driven PTEN-deficient and PTEN-intact mouse gliomas
generated in nestin-tv-a/ink4a-arf-/-/pten
fl/fl mice. First, we gener-
ated PTEN-deficient and PTEN-intact PDGF-B induced glioma
primary cultures (PIGPCs) and treated them with perifosine and
CCI-779 both individually and in combination. We showed when
these two drugs are combined, Akt and mTOR are uniformly
inhibited independent of PTEN status. The benefits of combining
perifosine and CCI-779 is further supported with in vivo data
generated by treating mice with GBMs for 5 days before
harvesting tumor tissue for immunoblot and IHC analysis. In vivo,
perifosine and CCI-779 continued to show synergy in inhibiting
the PI3K/mTOR axis corresponding with decreased tumor
proliferation and induction of apoptosis. We further monitored
the tumor response in vivo with MR imaging in PTEN-deficient
animals, which demonstrates that the combination induces the
greatest loss in tumor cellularity as reflected by changes in ADC
value.
Results
Generation of PDGF-B induced PTEN-deficient and PTEN-
intact high-grade gliomas in Ink4a/ARF null background
All experiments for this study utilized the RCAS/tv-a system to
generate PDGF-B driven gliomas in nestin-t-va/ink4a-arf-/-/pten
fl/fl
mice [34]. In this background, mice develop tumors with a 90–
95% incidence, resulting in the formation of high-grade gliomas
within 4–6 weeks post-injection. These tumors share high-grade
elements such as microvascular proliferation and pseudopalisading
necrosis with human GBMs [34,35] (Fig. 1A,B) These tumors
closely mimic the proneural subtype of GBM, in which CDKN2A
(encoding for both p16INK4A and p14ARF) and PTEN deletion are
observed in up to 56% and 69% proneural human gliomas,
respectively [36]. This model also resembles the human pathology
in that the tumors generated have abnormal and leaky vasculature,
resulting in variable disruption of the blood-brain barrier that can
be visualized and quantified by MRI [37]. In order to accurately
dissect the role of PTEN in the sensitivity of gliomas to mTOR
inhibition and Akt inhibition in vitro and in vivo, we utilized PDGF-
B driven PTEN-deficient and PTEN-intact gliomas. To achieve
PTEN deletion in the tumors, we introduced RCAS-Cre in
combination with RCAS-PDGF-B to nestin-t-va/ink4a-arf-/-/pten
fl/fl
mice, which generated tumors that were PTEN null (Fig. 1B). These
mice represent an excellent tool to investigate the role of
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backgrounds.
Perifosine and CCI-779 effectively combine to inhibit the
Akt and mTOR pathways in primary glioma cell cultures
in vitro
In order to determine whether perifosine and CCI-779 were
able to effectively inhibit their targeted pathways, we first
examined the effects of these inhibitors alone or in combination
in PDGF-B induced glioma primary cultures (PIGPCs) derived
from the mouse model described above. The cultures used in these
experiments were freshly isolated from tumors and passaged a
maximum of 5 times. Each PIGPC was generated by combing
three freshly isolated tumors, histologically validated to be GBM.
First, we performed immunoblots for decrease of pAkt and pS6RP
levels with various doses of CCI-779 and perifosine to determine
the dose response (data not shown). We chose 30 mM perifosine
and 1 nM CCI-779 because treating with those concentrations
resulted in reproducible and near complete inhibition of pAkt or
pS6RP. We then treated three independently generated PTEN-
intact (PTEN +/+) and three independent PTEN-deficient (PTEN
2/2) PIGPCs with perifosine and CCI-779 and quantified the
changes in pAkt and pS6RP levels to determine the uniformity and
statistical significance of the results (Fig. 2 B,D). Untreated
PIGPCs demonstrated baseline levels of pAkt and pS6RP, and
exposing the cultures to perifosine for four hours resulted in
significant decrease in pAkt levels in both PTEN +/+ and PTEN
2/2 lines by 282.83% (p,0.001) and 286.26% (p,0.05)
respectively. However, despite inhibition of pAkt, pS6RP levels
remained unaffected in PTEN +/+ glioma cultures. Interestingly,
in PTEN 2/2 glioma cultures, Akt inhibition resulted in
incomplete but statistically significant decrease in pS6RP levels
278.33% (p,0.001) (Fig. 2A,B,C,D). These results suggest a
differential sensitivity of mTOR in PTEN +/+ and PTEN2/2
glioma cultures to Akt inhibition.
After four hours of treatment with 1 nM CCI-779, pS6RP
levels were significantly decreased by 100% (p,0.001) and
98.83% (p,0.001) in PTEN +/+ and PTEN 2/2 cultures
respectively. In the case of PTEN +/+ cultures, treatment with
CCI-779 resulted in a significant increase in pAkt levels by
94.31% (p,0.001). These results demonstrate the existence of a
negative regulatory loop where mTOR inhibition induces the
activation of Akt in mouse gliomas, as shown to be the case in
various tumor types [22,38]. For the PTEN 2/2 cultures the
average pAkt increase was 24.46% but failed to reach statistical
significance, which can be partially explained with already high
levels of pAkt due to PTEN-deficiency. When PICPCs were
cultured with a combination of both perifosine and CCI-779,
both pAkt and pS6RP levels were simultaneously and significantly
Figure 1. Generation of PTEN wt and PTEN null gliomas using the RCAS/tv-a system. (A) Four-to-six week oldnestin-tv-a/ink4a-arf-/-/pten
fl/fl
mice are stereotactically injected with DF-1 cells expressing the RCAS-PDGF-B virus and from high-grade gliomas with PTEN intact. (B) Four-to-six week
oldnestin-tv-a/ink4a-arf-/-/pten
fl/flmicearestereotacticallyinjectedwithDF-1cellsexpressingtheRCAS-PDGF-Bvirus andDF-1cellsexpressingRCAS-Cre
virus and from high-grade tumors with PTEN deleted.
doi:10.1371/journal.pone.0014545.g001
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87.50% (p,.05) and pS6RP levels were reduced by 100%
(p,0.001) and 97.70% (p,0.001) in PTEN +/+ and PTEN 2/2
lines (Fig. 2A,B,C,D).
PDGF-driven gliomas display lower pAkt and pS6RP
levels when glioma-bearing mice are treated in vivo with
perifosine and CCI-779
Having established that perifosine and CCI-779 combine to
completely inhibit the PI3K/mTOR pathway in glioma cultures,
we next wanted to investigate if the two treatments maintained
their synergy when used to treat PDGF-B driven gliomas in vivo.
Twelve PTEN +/+ and twelve PTEN 2/2 glioma-bearing mice
were treated for 5 days by intraperitoneal injection of either
vehicle, 30 mg/kg perifosine, 40 mg/kg CCI-779, or a combina-
tion of both 30 mg/kg perifosine and 40 mg/kg CCI-779. The
animals were sacrificed 24 hours after the last treatment and the
tumor tissue was excised and frozen in liquid nitrogen. Once
frozen, the tumor was disrupted and lysed to allow for protein
collection and immunoblot analysis of changes in pAkt and pS6RP
levels (Fig. 3A,B). When both PTEN +/+ and PTEN 2/2
gliomas were treated with perifosine alone, pAkt levels decreased
by 23.79% and 43.13% respectively, although neither decrease
reached statistical significance, largely because of the variable pAkt
inhibition from tumor to tumor. This is likely due to variability in
pAkt levels between individual tumors, as well as the complications
of drug delivery caused by the BBB, which may be preventing
delivery of an adequate amount of drug to the tumor in vivo.W e
used the highest dose of perifosine tolerated by glioma bearing
mice as a single agent or in a combination treatment. Other
studies of in vivo perifosine activity have reported higher tolerated
doses, but those studies utilize subcutaneous tumors as opposed to
the intracranial tumors used in this current study [39]. When
PTEN +/+ and PTEN 2/2 tumors were treated with CCI-779,
pS6RP was significantly lowered by 100% (p.0.001) and by
82.29% (p..05), respectively. Interestingly, treating with CCI-779
alone did not increase measured levels of pAKT in either tumor
type. When PTEN +/+ and PTEN 2/2 tumors were treated for
5 days with a combination of perifosine and CCI-779, both pAkt
Figure 2. Combing perifosine and CCI-779 effectively inhibits both the Akt and mTOR pathways in primary glioma cultures treated
in vitro. (A) A representative immunoblot of PTEN +/+ primary GBM cell cultures after 4 hours with no treatment (NT), vehicle (V), 30 mM perifosine
(P), 1 nM CCI-779 (C) or combination of 30 mM perifosine and 1 nM CCI-779 (P+C). (B) Quantification of the changes in pAkt and pS6RP based on
three independent primary PTEN +/+ GBM cell cultures, with 20 mg protein per well. (C) A representative immunblot of PTEN -/- primary GBM cell
cultures after 4 hours with no treatment (NT), vehicle (V), 30 mM perifosine (P), 1 nM CCI-779 (C) or combination of 30 mM perifosine and 1 nM CCI-
779 (P+C). (D) Quantification of the change in pAKT and pS6RP based on three independent primary PTEN -/- GBM cultures, with 20 mg protein per
well.
doi:10.1371/journal.pone.0014545.g002
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p,0.001, 295.45% p,0.05) were significantly decreased. These
results demonstrate the enhanced ability of perifosine and CCI-
779 to inhibit the PI3K/mTOR pathway when used in vivo, and
the strongest pathway inhibition occurred when the treatments
were used in combination regardless of PTEN status.
Akt inhibition in combination with mTOR inhibition
results in cell death and cell cycle arrest in gliomas
We next examined the biological consequences of inhibiting the
PI3K/Akt/mTORaxisinPDGF-Bdrivengliomas.Tumor-bearing
mice with PTEN +/+ or PTEN 2/2 tumors were treated for 5
daysas described above(324 mice per group), and tumor tissue was
analyzed by immunohistochemistry (IHC) for evidence of cell
proliferation (anti-PCNA and anti-Ki67) and for cell death
(TUNEL). PCNA staining of PTEN +/+ and PTEN 2/2 gliomas
(Fig. 4A,B) demonstrated a slight qualitative decrease in prolifer-
ation for perifosine treated animals with a more profound decrease
seen in CCI-779 and in the combination treatment groups. The
levels of proliferation were further investigated using a second
marker for cellular proliferation, Ki67, which had the benefit of less
background staining. The Ki67 staining results mirrored those
obtained with PCNA, and served as a more accurate marker to use
for the quantification presented in the side graph (Fig. 4A,B).
Untreated PTEN +/+ tumors had a baseline Ki67 positivity of
16.52 +/2 3.12%, which was unchanged by perifosine (14.14 +/2
5.74%), but dramatically decreased by treatment with CCI-779 and
combination therapy (3.86 +/2 2.65% and 1.22 +/2 0.61%,
p.0.001). Thedecreased proliferation with CCI-779 coincideswith
a downregulationofpS6RP.PTEN2/2tumorshadahigherKi67
positivity (23.36 +/2 5.28%) that was not significantly changed by
perifosine (31.47 +/2 9.45% p=0.18). Treatment with CCI-779
again resulted in decreased levels of pS6RP, and Ki67 positivity was
decreased to 15.38 +/2 2.67%, though this was not statistically
significant. Interestingly, the decrease in proliferation with CCI-779
alone was less dramatic in the PTEN 2/2 tumors than in PTEN
+/+ tumors, as can be seen by both the PCNA and the Ki67
staining. When both drugs were combined to treat PTEN 2/2
gliomas, Ki67 positivity was significantly decreased to 5.46% +/2
1.29% (Fig. 4A,B).
Finally, TUNEL staining for the presence of apoptosis revealed
increased levels of cell death in tumors treated with perifosine in
both PTEN +/+ (5.25% increase) and PTEN 2/2 tumors (9.31%
increase), though the increases were not statistically significant due
to varying degrees of apoptosis from tumor to tumor (Fig. 4A,B).
This variability mirrors the variability in Akt inhibition seen in the
Figure 3. Combing perifosine and CCI-779 effectively decreases the levels of pAKT and pS6RP of gliomas treated in vivo. Immunoblot
analysis of (A) PTEN +/+ and (B) PTEN -/- tumors after mice with GBMs were treated for 5 days with either vehicle, 30 mg/kg perifosine, 40 mg/kg CCI-
779, or a combination of 30 mg/Kg perifosine with 40 mg/Kg CCI-779. The right panel shows the quantification of the changes in pAkt and pS6RP
based on comparing the average of each group to the vehicle treated tumors (n=3 mice per group).
doi:10.1371/journal.pone.0014545.g003
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variability in the drug’s delivery may lead to differing effectiveness
from tumor to tumor. CCI-779 treated mice did not demonstrate
increased TUNEL positivity. In both tumor types, the combina-
tion treatment group displayed statistically significant increase in
TUNEL positivity (PTEN +/+=10.60% increase, PTEN 2/2=
15.48% increase) (Fig. 4A,B). Independent of PTEN status, the
combination of perifosine and CCI-779 inhibited pS6RP signaling
while inducing a qualitative and quantitative decrease in prolife-
ration and increase in cell death.
Figure 4. PDGF-B-driven glimoas treated with the combination of perifosine and CCI-779 undergo cell death and have decreased
proliferation. Images of H&E, IHC with anti-p-S6RP, anti-PCNA, anti-Ki67, and TUNEL of (A) PTEN +/+ and (B) PTEN -/- GBMs after glioma-bearing
mice were treated in vivo for 5 days with either vehicle, 30 mg/Kg perifosine, 40 mg/Kg CCI-779, or a combination of 30 mg/Kg perifosine with
40 mg/Kg CCI-779. PCNA and Ki67 images are 200x with the black bar indicating 100 microns. The graph on the right shows quantification of Ki67
and TUNEL staining for 3-4 independent tumors. *,**, and *** represent significance determined by ANOVA analysis for p.0.05, p.0.01, and
p.0.001.
doi:10.1371/journal.pone.0014545.g004
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perifosine, CCI-779 and combination in PTEN-deficient
animals
Imaging studies were accomplished using the PTEN-deficient
gliomas model to evaluate the effects of P13K/mTOR pathway
inhibition on tumor growth rates and cellularity. In order to
characterize the in vivo tumor response, we followed tumors with
MR imaging during the treatment window. MR images of animals
in the four treatment groups were obtained daily during treatment
in order to follow both tumor volume and treatment-associated
alterations in tumor water diffusion values. Shown in Figure 5A
are representative contrast-enhancing MR images and the same
MR images with color overlay ADC maps of the tumors for each
of the treatment groups shown for 24 hours after the last treatment
dosage. Tumor volumes were obtained from the contrast-
enhanced images and plotted over time as shown in Figure 5B.
At day 3 post-treatment initiation, animals treated with CCI-779
either alone or in combination had generated a statistically smaller
tumor volume than controls (p,.05), which continued throughout
the study. By day 7, the perifosine treated cohort was found to
have a significantly larger tumor volume than both the CCI-779
and combination treatment cohorts. In contrast, perifosine treated
tumor volumes were not found to be different from controls at any
point during the study. The same was true between the CCI-779
treated groups.
DW-MRI was used to assess changes in tumor cellularity during
treatment. Quantitative DW-MRI maps are shown as color
overlays on their corresponding anatomical images in Figure 5A.
At day 2 post-treatment initiation, combination therapy had a
significant increase in ADC values from control values (p,.05). By
day 4, the combination therapy generated a significantly larger
percent change in ADC than perifosine treated animals. CCI-779
reached significantly higher ADC values versus control on day 5
post-initiation of treatment (Fig. 5C). No additional group
differences in the percent change in ADC values between groups
were found to be significant. Nevertheless, changes in ADC values
between combination and CCI-779 therapies had resulted in a
p=0.1 by day 5 post-treatment initiation.
Figure 5. In vivo imaging of therapeutic response using contrast enhanced diffusion weighted MRI. (A) MR gadolinium (Gd) contrast-
enhanced T1-weighted images and ADC color overlay maps demonstrate effects of in vivo effects of treatment with obtained from representative
control, perifosine, CCI-779 and combination (perifosine + CCI-779) treated glioma mice at 5-7 days post-initiation of therapy. (B) Plot of mean MRI-
determined tumor volumes based upon Gd-contrast enhanced regions versus time post-treatment initiation for control, perifosine, CCI-779 and
combination (perifosine + CCI-779) treated mice. (Error bars 6 SEM). (C) Plot of percent change of mean ADC values versus time post-treatment
initiation for control, perifosine, CCI-779 and combination (perifosine + CCI-779) treated mice. (Error bars 6 SEM).
doi:10.1371/journal.pone.0014545.g005
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Our studies using primary glioma cultures from PTEN-deficient
and PTEN-intact PDGF-B driven mouse GBMs demonstrate that
PTEN status influences mTOR’s sensitivity to Akt inhibition with
perifosine. When PTEN is intact, mTOR appears to be AKT
independent. Our data agrees with recent studies in EGFR driven
gliomas models that show mTOR can be regulated by the PKC
pathway independent of Akt phosphorylation [40]. Gliomas are
one of the many tumor types where selectively inhibiting key
signaling pathways appears to be a moving target. Recent studies
have shown that in response to therapy, gliomas undergo critical
changes in their molecular circuitry, such as loss of key tumor
suppressor proteins, the selection for kinase-resistant mutants, and
the deregulation of feedback loops [41]. Our model supports the
view that the presence or absence of a single regulatory
component, such as PTEN, is enough to shift the signaling
network, even in very similar tumors. However, tumors treated
with a combination of perifosine and CCI-779 had dramatically
decreased the levels of pAkt and pS6RP independent of PTEN
status.
Synergistic effects between rapamycin and LY294002, an PI3K
inhibitor that acts upstream of Akt, are commonly observed in vitro
[29,42], but confirming those results in clinically relevant in vivo
models has proved to be more difficult. Since perifosine was able
to penetrate the BBB in previous mouse glioma studies [7,33], we
were able to follow up on the effective synergy we observed in our
in vitro culture studies and investigate the effectiveness of this
combination in PTEN-intact and PTEN-deficient PDGF-B-driven
Ink4a-ARF-deficient gliomas in vivo. Five days of in vivo treatment
with perifosine resulted in variable but not statistically significant
decreases of pAkt levels. Similarly, perifosine alone caused a
variable and not statistically significant increase cell death. Since in
cell culture, perifosine decreased pAkt levels dramatically and in a
dose-dependant manner (data not shown), a possible explanation
of the lack of statistically significance in vivo could be as a result of
low drug concentrations in the tumor due to the BBB. To further
investigate this possibility, we treated tumor-bearing mice with a
single dose of 120 mg/kg perifosine, and immunoblot analysis
showed a statistically significant decrease in pAkt levels at 3 and
6 hours (data not shown). This further supports the hypothesis
that, in our model, perifosine levels are limited by the BBB, and
that we might be able to overcome this complication with an
increased dose of perifosine. However, these elevated doses of
perifosine were not well tolerated by the animals.
It is also worth addressing that, unlike the results observed in
culture, Akt inhibition caused by perifosine alone did not have a
drastically different effect when comparing the PTEN +/+ and
PTEN 2/2 tumors. One possible explanation for this discrepancy
is that the degree of Akt inhibition in vivo was much less dramatic
than that observed in culture. When performing experiments in
culture, we have precise control over both the concentration of the
drug and the length of exposure to the drug. These parameters
cannot be fully reproduced in vivo. While the exact cause for the
discrepancy between these findings is a potential area for future
study, it was encouraging that significant Akt inhibition was
achieved when combined with CCI-779, further supporting the
rational for using the combination of these inhibitors.
In contrast to perifosine, CCI-779 was much more consistent as
a single agent, suggesting the BBB was not a complicating factor
for this compound. This correlates with human clinical data, were
CCI-779 has been shown to effectively penetrate the BBB of
patients with recurrent glioblastoma [43]. Treating animals for 5
days with 40 mg/kg decreased pS6RP levels in tumors indepen-
dent from PTEN status, and the decrease in pS6RP corresponded
with a decreased cellular proliferation rate. Of note, this effect was
more dramatic in PTEN intact tumors, as demonstrated by both
PCNA and Ki67 staining. While gliomas treated with CCI-779 in
vivo did show decreased pS6RP, they did not show increased pAkt
levels. Interestingly, our results did not completely reproduce data
observed by Cloughsey et al [21] where fourteen recurrent PTEN
null GBMs were biopsied both before and after treatment with
rapamycin, in which half of the patients had no change in Akt
activity and half had a slight increase in Akt activity. Although the
human GBMs were selected based on PTEN status, they were not
selected based on their molecular subgroup status. Recent studies
have clearly shown at least three distinct subtypes of GBM, and
these subtypes have very different molecular and signaling
profiles[36,44]. By contrast, our study specifically focuses on
PDGF-driven gliomas in the hope to better understand how the
human PDGF-subgroup will respond to therapy. However, we do
not believe we can compare our results in modeling PDGF-driven
glioma to all subtypes of glioma, and thus we cannot compare our
results directly to the previous human clinical trials.
When the two drugs were combined in vivo for 5 days, both pAkt
and pS6RP levels were significantly decreased independent of
PTEN status. This coincided with a striking decrease in cellular
proliferation and a marked increase in cell death, although the
relative decrease in proliferation and increase in cell death was
greatest in PTEN null tumors. Therefore, we utilized PTEN-
deficient tumors and MR-imaging to monitor the dynamics of the
tumor response in real time by monitoring in vivo changes in
cellularity and apparent diffusion value (ADC) changes and
imaging characteristics. MRI allowed for tumor staging and thus
gliomas could be entered into the study at a similar size, providing
an opportunity to follow changes in tumor volumes over time for
each of the four animal cohorts. In Figure 5, the quantified
diffusion values are provided as ADC values and were overlayed
on the corresponding anatomical image in order to visualize the
spatial variations of the changes within the tumor mass. If tumor
cell killing occurs during treatment intervention, ADC values will
increase in those regions of the tumor affected. What Figure 5
specifically shows is that the ADC values progressively increased
from controls to Perifosine to CCI to combination therapy, as
visualized by the increased intensity represented by the red regions
in the image. As the ADC values are a reflection of the rate of
cellular removal, these results indicate a progressive loss of cell
viability over these 4 cohorts of animals.
It is interesting to note that tumor volume continued to gain
during the treatment period, despite the marked increase in
diffusion values. Since the gliomas had a rapid proliferation rate, it
may be possible that the rate of cell removal, as evidenced by the
increased ADC values (red regions in the color images), never
quite overcame the rate of cellular proliferation, even in the
combination treatment group. In the current study, changes in
ADC values appear to correlate well with the reduction of tumor
growth rates and serve as an indication of the efficacy of the
treatment. Although overall tumor volume did not shrink, ADC
values proved to be an exquisitely sensitive measurement for
comparing different treatments, and this imaging biomarker can
be easily implemented in clinical translation of promising
therapies. We would anticipate that future treatments capable of
producing tumor mass shrinkage would be reflected as an even
greater response in tumor ADC values, and that this strategy
would serve as a foundation on which to non-invasively monitor
novel treatment protocols. Thus, DW-MRI may provide an
opportunity to assess early treatment response in patients treated
with agents targeting the PI3K/Akt/mTOR pathways.
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notion that the best clinical potential for inhibiting the PI3K/
Akt/mTOR will be reached when multiple components of the
pathway are inhibited and that DW-MRI may be used as an
early imaging response biomarker to provide quantitative and
spatial information related to tumor cell death during treatment
administration. Furthermore, our studies represent the murine
portion of a co-clinical trial where the human part of the trial is
currently being run at Memorial Sloan Kettering Cancer Center
[NCT01051557]. The trial is recruiting adults with recurrent
gliomas to be treated with CCI-779 and perifosine as salvage
therapy. Therefore, further insight as to how these two inhibitors
work together, specifically in a PDGF-driven glioma model, is of
significant importance to understanding the potential impact on
the human disease.
Materials and Methods
Ethics Statement
All of the animal experiments were conducted using protocols
approved by the Institutional Animal Care and Use Committees of
Memorial Sloan-Kettering Cancer Center and the University of
Michigan Medical School. The approved protocols are 00-11–189
(MSKCC, last approved 3/15/2010) and 09583 (UMMS, last
approved 11/25/09).
Cell culture and transfection
Df-1 cells were purchased from ATCC. Cells were grown at
39uC according to ATCC instructions. Transfections with RCAS-
PDGF-B-HA or RCAS-Cre were performed using Fugene 6
transfection kit (Roche # 11814443001) according to manufac-
tures instructions.
Generation of tumors using RCAS/tv-a
4–6 week-old nestin-tv-a/ink4a-arf-/-/pten
fl/fl mice were anesthe-
tized with ketamine (0.1 mg/g) and xylazine (0.02 mg/g) and
injected using stereotactic fixation device (Stoelting, Wood Dale,
IL). One microliter of RCAS-PDGF-B or 1:1 mixture of 4 610
4
RCAS-PDGF-B and RCAS-Cre transfected DF1 cells was
delivered using a 30-gauge needle attached to a Hamilton syringe.
Cells were injected to the right frontal cortex, coordinates bregma
1.7 mm, Lat 20.5 mm, and a depth 1.5 mm. Mice were
monitored carefully and sacrificed when they displayed symptoms
of tumor development (lethargy, head tilt).
Generation of PDGF-B driven primary gliomas cultures
Tumors were dissected and enzymatically digested in Hanks
balanced salt solution containing 12% papain and 10 mg/ml
DNase at 37uC for 15 min, with subsequent inactivation using
ovomucoid (1 mg/mL) (Worthington, Lakewood, NJ, USA). The
cell suspension was consecutively washed and resuspended to
obtain a single cell suspension, which was resuspended in DMEM
media containing 10% FBS, 2 mM L-glutamine, 100 units/mL
penicillin, and 100 mg/mL streptomycin.
Drug administration
Tumor-bearing mice received intraperitoneal injection of
30 mg/kg Perifosine (Keryx Biopharmaceuticals, NY) in 0.9%
NaCl daily for 5 days. CCI-779 (Wyeth, Pearl River, NY) was
given through intraperitoneal injection daily at the dose of 40 mg/
kg for 5 days. The drug was first dissolved to 50 mg/ml in 100%
ethanol and then diluted to 2 mg/ml with 5% Tween-80 (Sigma)
and 5% polyethylene glycol-400 (Sigma). For combination
treatment, mice received 30 mg/kg perifosine and 40 mg/kg
CCI-779 simultaneously for 5 days.
Tissue Processing
Animals used for histological analysis and immunoblot analysis
were sacrificed 24 hours after the last dose of drug treatment and
transcardially perfused with 4uC PBS. At this point, tumors for
western analysis were excised and frozen in liquid nitrogen and
tumors for histological analysis were further perfused with 10%
neutral buffered formalin before being excised and fixed for
72 hours. Fixed tissues were then embedded in paraffin. Formalin-
fixed, paraffin embedded specimens were serially sectioned, 5 mm
slides were mounted.
Immunoblot Analysis
For cell culture analysis, low passage PIGPCs (p#5) were plated
in DMEM media with 1% FBS and treated with either
DMSO+PBS, perifosine, CCI-779, or combination. After 4 hours,
the cells were rinsed twice with PBS and scraped into lysis buffer
(1% NP-40, 0.1% Triton X-100, 150 mM NaCl, 50 mM Tris
pH 7.5, 1 mM EDTA, 1 mM PMSF, 1 mM Na3VO4, 250 mM
NaF). For in vivo tumor analysis, fresh frozen tumors were
manually disrupted with a mortar and pestle and resuspended in
lysis buffer. For each sample, 20 mg of lysate was loaded for SDS-
PAGE and transferred to a PVDF membrane. The antibodies
used included anti-phospho-Akt (Ser
473) (Cell Signaling #4060),
anti-phospho-S6RP (Ser
235/236) (Cell Signaling #4856), anti-Akt
(Cell Signaling #4685), anti-S6RP (Cell Signaling #2217), anti-
actin (Chemicon MAB1501). Immunoblots were quantified using
ImageJ software [45].
Immunohistochemistry
For immunohistochemical detection, an automated staining
processor was used (Discovery, Ventana Medical Systems, Inc.).
The protocols were established at the Molecular Cytology Core
Facility and Eric Holland laboratory at MSKCC. Primary
antibodies used were anti-pS6RP 1:300 (Cell Signaling, # 2211),
anti-PCNA 1:2000 (DAKO Cat# M0879), anti-PTEN 1:100 (Cell
signaling, #9559), and anti-Ki67 1:200 (Dako Cat.# M7240).
Ki67 quantification was performed using HistoFACS and
HistoQUEST and HistoFACS software (TissueGnostics), and four
tumors were analyzed for each group.
TUNEL assay
The terminal deoxynucleotidyl transferase-mediated dUTP-
biotin nick-end labeling (TUNEL) assay was performed on 5 mm
sections by using Terminal Transferase, recombinant kit (Roche,
#3333566) in accordance with the manufacturer’s protocol.
TUNEL quantification was performed HistoFACS and Histo-
QUEST and HistoFACS software (TissueGnostics) and four
tumors were analyzed for each group.
MRI Image Processing and Analysis
MRI scans were performed on a 9.4T, 16 cm horizontal bore
Varian, Inc (Palo Alto, CA) Direct Drive system with a SAW mouse
head coil (m2m Imaging, Corp., Cleveland, OH). During all MRI
procedures, the animals were anesthetized with 1–2% isoflurane/
air mixture, and body temperature was maintained using a heated
air system (Air-Therm Heater, World Precision Instruments,
Sarasota, FL). MR images were acquired prior to treatment
initiation, daily for a week and every other day thereafter till the
animal expired or became moribund and was then sacrificed.
Each MRI experiment per animal consisted of a contrast-
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tumor from healthy brain tissue, and a diffusion weighted MRI
sequence.
Contrast-enhanced T1-weighted spin-echo images were ac-
quired with the following parameters: Repetition time/echo time
(TR/TE)=85/3.2 ms, field of view (FOV)=30 mm, matrix size
=128664, slice thickness =1 mm, 13 slices and number of scans
=2. Contrast-enhancement was performed by i.p. administration
of 50 ml of 0.5 M gadolinium-DTPA (Magnevist, Bayer Health-
care Pharmaceuticals, Wayne, N.J) 2 minutes prior to image data
acquisition.
Diffusion-weighted images were acquired using a spin-echo
sequence, with motion correction using a navigator echo and
gradient waveforms sensitive to isotropic diffusion, with the
following parameters: TR/TE =4000/47 ms, FOV =30 mm,
matrix size =128664, slice thickness =1 mm and b-values
(diffusion weighting) of 120 and 1200 s/mm
2.
Volumes of interest (VOIs) were contoured around the
enhancing rim of the tumors on the contrast-enhanced T1-
weighted images for volume measurements and determination of
whole-tumor means of ADC. ADC was calculated from two
diffusion weightings (b-values) as previously described [26].
Diffusion measurements were calculated as means over the tumor
volume. All image reconstruction and digital image analysis was
accomplished using in-house programs developed in the software
application Matlab (The Mathworks, Natick, MA, USA).
Statistics
Graphs have been made using GraphPad Prism 4 (GraphPad
Software, San Diego, CA) and analyzed using ANOVA.
Figure 1C,F; Figure 2A,B; Figure 3A,B were analyzed used
Dunnett’s Multiple Comparison Test of ANOVA, which com-
pares all columns versus control column. Statistical analysis of the
MRI analysis utilized ANOVA with a Bonferroni post hoc test to
account for multiple comparisons. Group comparisons of percent
change in tumor volume and ADC were assessed at individual
time points using an independent sample Student’s t-test. All
statistical computations were performed with a statistical software
package (SPSS Software Products, Chicago, IL). *=p,0.05,
**=p,0.01, ***=p,0.001, absence of star=not significant.
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